Tirzepatide reduces weight more than semaglutide in head-to-head trial of patients without diabetes

The findings were robust, said endocrinologist Professor Gary Wittert.

Tirzepatide leads to greater weight loss than semaglutide in adults with obesity but without type 2 diabetes, a head-to-head trial suggests.

Published in the New England Journal of Medicine, the SURMOUNT-5 trial involved 751 participants randomly assigned to the maximum tolerated dose of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) and treated for 72 weeks.

Participants also received lifestyle counselling.

The open-label trial, funded by tirzepatide maker Eli Lilly, found average weight loss with tirzepatide was 20.2% of body weight, or 22.8kg.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .